there is unlikely to be major confusion between the two groups.

The limb-girdle muscular dystrophies (LGMD) are a group of autosomally inherited progressive myopathic diseases. Eight different genetic types of LGMD have so far been identified, of which two are dominantly inherited and the other six recessively inherited.¹ Of the genes so far identified, three encode structural proteins of the dystrophin associated glycoprotein complex and one encodes the muscle specific calpain. Clinically, there are insufficient data so far to distinguish between the different forms of LGMD.

In the past, LGMD has been confused with other forms of muscle disease. Patients previously diagnosed as suffering from LGMD have in some cases been shown by molecular analysis to have a dystrophinopathy (X linked) or mitochondrial or metabolic disease.

Given the extreme heterogeneity of LGMD, it is important to ensure that resources applied to track down the primary genetic defect in any particular family or case are appropriately directed by careful exclusion of all possible alternative diagnoses. It has been postulated that the milder forms of spinal muscular atrophy (type III SMA) may be a source of diagnostic confusion in recessive or sporadic cases. Phenotypically, both diseases show proximal muscle weakness and wasting, creatine kinase levels may be raised in SMA, and EMG and muscle biopsy analysis may show conflicting or confusing results.

It is now possible to perform molecular tests for the genetic faults which are associated with chromosome 5 linked SMA. We examined a panel of 95 patients with a diagnosis of LGMD. These patients were from a variety of different sources both in the UK and abroad. Some referred themselves to our department because of our research interest in LGMD, others were referred from recognised neuromuscular units. All, according to the information available, had clinical characteristics and investigations which were consistent with a diagnosis of LGMD according to the latest diagnostic criteria.²

We analysed DNA samples for deletions of exons 7 and 8 of the survival motor neurone (SMN) gene (deleted in approximately 94% of milder SMA cases)³ and also for deletions of exons 5 and 6 of the neuronal apoptosis inhibitory protein (NAIP) gene (deleted in about 67% of SMA type 1 cases and 42% of type 2 and 3 cases).⁴ We found deletions in SMN and NAIP in only one family. Haplotype analysis confirmed that the affected sibs in this family did share the chromosome 5 region containing the SMN and NAIP genes. The three children from this family had childhood onset of a predominantly proximal muscle weakness and wasting diagnosed clinically and on investigation as a limb-girdle muscular dystrophy. Recent re-evaluation of serum creatine kinase showed that the level remained high (576 IU/l, normal up to 180 IU/l) even many years after the onset. All had relatively slow progression of disease and normal intelligence.

We conclude that spinal muscular atrophy associated with deletions of SMN and NAIP is not a common source of confusion in the diagnosis of LGMD. The investigation may, however, still be useful in those families in which there is genuine diagnostic confusion on the basis either of equivocal creatine kinase levels or conflicting results from EMG or muscle biopsy.

We are very grateful to the patients and clinicians who have helped collect the samples for this and other studies. Financial support has been provided by the Medical Research Council of Great Britain, the Muscular Dystrophy Group of Great Britain and Northern Ireland, and the British Medical Association.

R POGUE
T JACKSON
B SAYLI
A CURTIS
K M D BUSHBY

Department of Human Genetics, University of
Newcastle upon Tyne, 19/20 Claremont Place,
Newcastle upon Tyne NE2 4AA, UK

- 1 Bushby K, Beckmann JS. Report of the 30th and 31st ENMC International Workshops. *Neuromusc Disord* 1995;5:337-44.
- 2 Bushby K. Diagnostic criteria for the limb-girdle muscular dystrophies: report of the ENMC Consortium on limb-girdle muscular dystrophies. *Neuromusc Disord* 1995;5:71-4.
- 3 Lefebvre S, Burgler L, Reboullet S, *et al*. Identification and characterisation of a spinal muscular atrophy-determining gene. *Cell* 1995;80:155-65.
- 4 Roy N, Mahadeva MS, McLean M, *et al*. The gene for neuronal apoptosis inhibitory protein (NAIP), a novel protein with homology to baculoviral inhibitors of apoptosis, is partially deleted in individuals with type 1, 2 and 3 spinal muscular atrophy. *Cell* 1995;80:167-78.

BOOK REVIEWS

If you wish to order or require further information regarding the titles reviewed here, please write to or telephone the BMJ Bookshop, PO Box 295, London WC1H 9JR. Tel 0171 383 6244. Fax 0171 383 6662. Books are supplied post free in the UK and for BFPO addresses. Overseas customers should add 15% for postage and packing. Payment can be made by cheque in sterling drawn on a UK bank or by credit card (Mastercard, Visa, or American Express) stating card number, expiry date, and full name. (The price and availability are occasionally subject to revision by the Publishers.)

Cell Therapy. Editors G Morstyn, W Sheridan. (£70.00, US\$100.00.) Cambridge: Cambridge University Press. 1996. ISBN 0-521-47314-2.

It has been predicted that in the coming decade cell based therapies will begin to rival traditional pharmaceuticals in many areas of medicine but especially oncology. This timely book largely succeeds in its goal of providing a snapshot of this rapidly expanding field. The more than 70 contributors are authorities in the field and this amply compensates for the inevitable variation in how up to date the material is.

The book is organised into sections covering overlapping scientific, technical, and clinical aspects of haematopoietic cell therapy and immunotherapy introduced by succinct reviews of relevant aspects of the haematopoietic and immune systems by Moore and Slavin. The main body of the book is devoted to laboratory and clinical aspects of haematopoietic cell therapy starting with excellent reviews of progenitor assays, flow cytometry, and gene transfer technology. Mobilisation of peripheral blood progenitor cells, perhaps the major advance in haematology in the last decade, is well covered in a series of chapters by Shpall, To, and Sheridan and this is

followed by reviews of cell selection, purging, and expansion by some of the innovators and authorities in the field. The reason for the development of these technologies is, of course, that they facilitate dose intensification strategies in the treatment of malignant disease, and approaches to this involving growth factor and cellular support in a variety of diseases are covered next. Discussion of future applications of haematopoietic cell therapy is restricted to gene therapy and cellular therapy of HIV disease, areas in which success to date has been modest to say the least. Techniques for the generation of dendritic cells, perhaps one of the most promising new developments, are scarcely mentioned and this must count as a major omission. The final section of the book concentrates on experimental and clinical aspects of immunotherapy with coverage of neutrophil transfusion, tumour vaccines, and adoptive immunotherapy with autologous T and natural killer cells and allogeneic cells in the context of bone marrow transplantation.

Inevitably some relevant topics are not covered. As noted above, dendritic cells are only mentioned in passing and a chapter on T cell depletion, perhaps the commonest type of "graft engineering" currently performed, would have been helpful. Regulatory issues do vary from country to country but there are common safety concerns and discussion of these would also have been useful. Overall, however, these omissions do not detract from the value of the book which will be of interest to scientists, clinicians, and those in the biotechnology and pharmaceutical industries.

STEPHEN DEVEREUX

DNA and Protein Sequence Analysis. Editors M J Bishop, C J Rawlings. (£29.95.) Oxford: Oxford University Press. 1997. ISBN 0-19-963463-7.

This book is intended for biologists wishing to understand more about molecular biology databases and methods of sequence analysis. As the editors state in their preface, it is 10 years since the publication of the similarly titled "Nucleic Acid and Protein Sequence Analysis" in this series and a new volume is certainly welcome. There are very few books covering this area and information is scattered in original papers and software manuals. On the technical side, one of the most noticeable changes in working methods has been the use of the World Wide Web to access databases and software. I felt that while the preface emphasised this, some of the earlier chapters that concentrated heavily on software were rather dated, partly as a result of the time taken to publish such a book.

It would have been helpful to have a longer introduction to the book to tie together the material. For example, there was no explanation of why one chapter was devoted to software for the Macintosh (10 years ago a similar chapter referred to the PC). There is a wide variation in style between authors and in the prior mathematical and computing knowledge assumed. Some biologists will undoubtedly feel that much of this book is about theory and not practice, though this is very much a feature of the subject.

Many of the later chapters give a better balance between the theoretical background and the software to perform the analyses. This was especially true of the chapter on Phylogenetic Estimation by Dr N Goldman,